APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cell-Free Circulating Tumor DNA (ctDNA)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cell-Free Circulating Tumor DNA (ctDNA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 17408777032 May 2026191 pages

Choose your research edition.

Industry ResearchCell-Free Circulating Tumor DNA (ctDNA) Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell-Free Circulating Tumor DNA (ctDNA) Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell-Free Circulating Tumor DNA (ctDNA) Market Analysis and Forecast 2026-2032227 pages · $4,950 USD

Market perspective

The global Cell-Free Circulating Tumor DNA (ctDNA) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Cell-Free Circulating Tumor DNA (ctDNA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cell-Free Circulating Tumor DNA (ctDNA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cell-Free Circulating Tumor DNA (ctDNA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cell-Free Circulating Tumor DNA (ctDNA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cell-Free Circulating Tumor DNA (ctDNA) include Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis and QIAGEN, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Cell-Free Circulating Tumor DNA (ctDNA) market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cell-Free Circulating Tumor DNA (ctDNA) and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cell-Free Circulating Tumor DNA (ctDNA) revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Cell-Free Circulating Tumor DNA (ctDNA) market size, projected growth trends, production technologies, key applications, and end-use industries.

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Company

Nexomics

Roche

ORIOMICS

Signatera

Illumina

Sysmex Corporation

Bio-Rad

Biocartis

QIAGEN

GuardantHealth

GSK plc

AstraZeneca

NeoGenomics Laboratories

AmoyDx

Annoroad

Burning Rock Biotech

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Type

Gastric Cancer Methylation Screening

Esophageal Cancer Methylation Screening

Colorectal Cancer Methylation Screening

Lung Cancer Methylation Screening

Liver Cancer Methylation Screening

Other Cancer Screening

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Application

Hospital

Medical Center

Laboratory

Cell-Free Circulating Tumor DNA (ctDNA) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell-Free Circulating Tumor DNA (ctDNA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell-Free Circulating Tumor DNA (ctDNA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell-Free Circulating Tumor DNA (ctDNA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Cell-Free Circulating Tumor DNA (ctDNA) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cell-Free Circulating Tumor DNA (ctDNA) industry.

Chapter 3: Detailed analysis of Cell-Free Circulating Tumor DNA (ctDNA) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cell-Free Circulating Tumor DNA (ctDNA)revenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Gastric Cancer Methylation Screening Table 3. Key Players of Esophageal Cancer Methylation Screening Table 4. Key Players of Colorectal Cancer Methylation Screening Table 3. Key Players of Lung Cancer Methylation Screening Table 4. Key Players of Liver Cancer Methylation Screening Table 5. Key Players of Other Cancer Screening Table 6. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 7. Key Players of Hospital Table 8. Key Players of Medical Center Table 9. Key Players of Laboratory Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & (US$ Million) Table 12. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2021-2026) Table 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2027-2032) & (US$ Million) Table 14. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2027-2032) Table 15. Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends Table 16. Cell-Free Circulating Tumor DNA (ctDNA) Industry Drivers Table 17. Cell-Free Circulating Tumor DNA (ctDNA) Industry Opportunities and Challenges Table 18. Cell-Free Circulating Tumor DNA (ctDNA) Industry Restraints Table 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Company (US$ Million) & (2021-2026) Table 20. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Company (2021-2026) Table 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Key Company Head Office and Area Served Table 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Company, Product Type & Application Table 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global Cell-Free Circulating Tumor DNA (ctDNA) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (US$ Million) Table 29. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2027-2032) & (US$ Million) Table 30. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2021-2026) Table 31. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2027-2032) Table 32. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (US$ Million) Table 34. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2027-2032) & (US$ Million) Table 35. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2021-2026) Table 36. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2027-2032) Table 37. Nexomics Company Information Table 38. Nexomics Business Overview Table 39. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 41. Nexomics Recent Development Table 42. Roche Company Information Table 43. Roche Business Overview Table 44. Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 46. Roche Recent Development Table 47. ORIOMICS Company Information Table 48. ORIOMICS Business Overview Table 49. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 51. ORIOMICS Recent Development Table 52. Signatera Company Information Table 53. Signatera Business Overview Table 54. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 56. Signatera Recent Development Table 57. Illumina Company Information Table 58. Illumina Business Overview Table 59. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 61. Illumina Recent Development Table 62. Sysmex Corporation Company Information Table 63. Sysmex Corporation Business Overview Table 64. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 66. Sysmex Corporation Recent Development Table 67. Bio-Rad Company Information Table 68. Bio-Rad Business Overview Table 69. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 71. Bio-Rad Recent Development Table 72. Biocartis Company Information Table 73. Biocartis Business Overview Table 74. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 76. Biocartis Recent Development Table 77. QIAGEN Company Information Table 78. QIAGEN Business Overview Table 79. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 81. QIAGEN Recent Development Table 82. GuardantHealth Company Information Table 83. GuardantHealth Business Overview Table 84. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 86. GuardantHealth Recent Development Table 87. GSK plc Company Information Table 88. GSK plc Business Overview Table 89. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 91. GSK plc Recent Development Table 92. AstraZeneca Company Information Table 93. AstraZeneca Business Overview Table 94. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 95. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 96. AstraZeneca Recent Development Table 97. NeoGenomics Laboratories Company Information Table 98. NeoGenomics Laboratories Business Overview Table 99. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 100. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 101. NeoGenomics Laboratories Recent Development Table 102. AmoyDx Company Information Table 103. AmoyDx Business Overview Table 104. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 105. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 106. AmoyDx Recent Development Table 107. Annoroad Company Information Table 108. Annoroad Business Overview Table 109. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 110. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 111. Annoroad Recent Development Table 112. Burning Rock Biotech Company Information Table 113. Burning Rock Biotech Business Overview Table 114. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 115. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio Table 116. Burning Rock Biotech Recent Development Table 117. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (US$ Million) Table 118. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2027-2032) & (US$ Million) Table 119. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (US$ Million) Table 120. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2027-2032) & (US$ Million) Table 121. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) Table 123. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032) Table 124. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (US$ Million) Table 125. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2027-2032) & (US$ Million) Table 126. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (US$ Million) Table 127. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2027-2032) & (US$ Million) Table 128. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) Table 130. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032) Table 131. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (US$ Million) Table 132. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2027-2032) & (US$ Million) Table 133. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (US$ Million) Table 134. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2027-2032) & (US$ Million) Table 135. Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (US$ Million) Table 136. Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2027-2032) & (US$ Million) Table 137. Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (US$ Million) Table 138. Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2027-2032) & (US$ Million) Table 139. Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) Table 141. Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032) Table 142. South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (US$ Million) Table 143. South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2027-2032) & (US$ Million) Table 144. South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (US$ Million) Table 145. South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2027-2032) & (US$ Million) Table 146. South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) Table 148. South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032) Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Cell-Free Circulating Tumor DNA (ctDNA) Product Image Figure 2. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type: 2025 VS 2032 Figure 4. Gastric Cancer Methylation Screening Image Figure 5. Esophageal Cancer Methylation Screening Image Figure 6. Colorectal Cancer Methylation Screening Image Figure 7. Lung Cancer Methylation Screening Image Figure 8. Liver Cancer Methylation Screening Image Figure 9. Other Cancer Screening Image Figure 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application: 2025 VS 2032 Figure 12. Hospital Image Figure 13. Medical Center Image Figure 14. Laboratory Image Figure 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region: 2025 VS 2032 Figure 18. Years Considered Figure 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Players in 2025 Figure 20. Global Top 5 and 10 Cell-Free Circulating Tumor DNA (ctDNA) Players Market Share by Revenue in 2025 Figure 21. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2021-2032) Figure 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2021-2032) Figure 26. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 27. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type (2021-2032) Figure 28. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2021-2032) Figure 29. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032) Figure 30. United States Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 31. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 32. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 33. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 34. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type (2021-2032) Figure 35. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2021-2032) Figure 36. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032) Figure 37. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 38. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 39. U.K. Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 40. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 41. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 42. Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 43. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 44. China Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type (2021-2032) Figure 45. China Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2021-2032) Figure 46. Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 47. Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type (2021-2032) Figure 48. Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2021-2032) Figure 49. Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032) Figure 50. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 51. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 52. Taiwan Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 53. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 54. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 55. Australia Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type (2021-2032) Figure 58. South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2021-2032) Figure 59. South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032) Figure 60. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 61. South Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 62. Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 63. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 64. Argentina Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 65. UAE Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 66. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 67. Chile Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032) & (US$ Million) Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Gastric Cancer Methylation Screening
  • Esophageal Cancer Methylation Screening
  • Colorectal Cancer Methylation Screening
  • Lung Cancer Methylation Screening
  • Liver Cancer Methylation Screening
  • Other Cancer Screening
Applications
  • Hospital
  • Medical Center
  • Laboratory
Companies covered
  • Nexomics
  • Roche
  • ORIOMICS
  • Signatera
  • Illumina
  • Sysmex Corporation
  • Bio-Rad
  • Biocartis
  • QIAGEN
  • GuardantHealth
  • GSK plc
  • AstraZeneca
  • NeoGenomics Laboratories
  • AmoyDx
  • Annoroad
  • Burning Rock Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Gastric Cancer Methylation Screening
  5. 1.2.3 Esophageal Cancer Methylation Screening
  6. 1.2.4 Colorectal Cancer Methylation Screening
  7. 1.2.5 Lung Cancer Methylation Screening
  8. 1.2.6 Liver Cancer Methylation Screening
  9. 1.2.7 Other Cancer Screening
  10. 1.3 Market Analysis by Application
  11. 1.3.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital
  13. 1.3.3 Medical Center
  14. 1.3.4 Laboratory
  15. 1.4 Global Market Growth Prospects
  16. 1.5 Global Cell-Free Circulating Tumor DNA (ctDNA) Growth Trends by Region
  17. 1.5.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region: 2021 VS 2025 VS 2032
  18. 1.5.2 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026)
  19. 1.5.3 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2027-2032)
  20. 1.6 Assumptions and Limitations
  21. 1.7 Study Goals and Objectives
  22. 1.8 Years Considered
2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Dynamics
  1. 2.1 Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends
  2. 2.2 Cell-Free Circulating Tumor DNA (ctDNA) Industry Drivers
  3. 2.3 Cell-Free Circulating Tumor DNA (ctDNA) Industry Opportunities and Challenges
  4. 2.4 Cell-Free Circulating Tumor DNA (ctDNA) Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Company (2021-2026)
  2. 3.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Key Company Head office and Area Served
  4. 3.4 Global Cell-Free Circulating Tumor DNA (ctDNA) Company, Product Type & Application
  5. 3.5 Global Cell-Free Circulating Tumor DNA (ctDNA) Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Cell-Free Circulating Tumor DNA (ctDNA) Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Cell-Free Circulating Tumor DNA (ctDNA) Tier 1, Tier 2, and Tier 3
4 Cell-Free Circulating Tumor DNA (ctDNA) Market by Type
  1. 4.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2032)
  3. 4.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Type (2021-2032)
5 Cell-Free Circulating Tumor DNA (ctDNA) Market by Application
  1. 5.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2032)
  3. 5.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Nexomics
  2. 6.1.1 Nexomics Company Information
  3. 6.1.2 Nexomics Business Overview
  4. 6.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  6. 6.1.5 Nexomics Recent Developments
  7. 6.2 Roche
  8. 6.2.1 Roche Company Information
  9. 6.2.2 Roche Business Overview
  10. 6.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  12. 6.2.5 Roche Recent Developments
  13. 6.3 ORIOMICS
  14. 6.3.1 ORIOMICS Company Information
  15. 6.3.2 ORIOMICS Business Overview
  16. 6.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  18. 6.3.5 ORIOMICS Recent Developments
  19. 6.4 Signatera
  20. 6.4.1 Signatera Company Information
  21. 6.4.2 Signatera Business Overview
  22. 6.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  24. 6.4.5 Signatera Recent Developments
  25. 6.5 Illumina
  26. 6.5.1 Illumina Company Information
  27. 6.5.2 Illumina Business Overview
  28. 6.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  30. 6.5.5 Illumina Recent Developments
  31. 6.6 Sysmex Corporation
  32. 6.6.1 Sysmex Corporation Company Information
  33. 6.6.2 Sysmex Corporation Business Overview
  34. 6.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  36. 6.6.5 Sysmex Corporation Recent Developments
  37. 6.7 Bio-Rad
  38. 6.7.1 Bio-Rad Company Information
  39. 6.7.2 Bio-Rad Business Overview
  40. 6.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  42. 6.7.5 Bio-Rad Recent Developments
  43. 6.8 Biocartis
  44. 6.8.1 Biocartis Company Information
  45. 6.8.2 Biocartis Business Overview
  46. 6.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  48. 6.8.5 Biocartis Recent Developments
  49. 6.9 QIAGEN
  50. 6.9.1 QIAGEN Company Information
  51. 6.9.2 QIAGEN Business Overview
  52. 6.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  54. 6.9.5 QIAGEN Recent Developments
  55. 6.10 GuardantHealth
  56. 6.10.1 GuardantHealth Company Information
  57. 6.10.2 GuardantHealth Business Overview
  58. 6.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  60. 6.10.5 GuardantHealth Recent Developments
  61. 6.11 GSK plc
  62. 6.11.1 GSK plc Company Information
  63. 6.11.2 GSK plc Business Overview
  64. 6.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  66. 6.11.5 GSK plc Recent Developments
  67. 6.12 AstraZeneca
  68. 6.12.1 AstraZeneca Company Information
  69. 6.12.2 AstraZeneca Business Overview
  70. 6.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  72. 6.12.5 AstraZeneca Recent Developments
  73. 6.13 NeoGenomics Laboratories
  74. 6.13.1 NeoGenomics Laboratories Company Information
  75. 6.13.2 NeoGenomics Laboratories Business Overview
  76. 6.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  78. 6.13.5 NeoGenomics Laboratories Recent Developments
  79. 6.14 AmoyDx
  80. 6.14.1 AmoyDx Company Information
  81. 6.14.2 AmoyDx Business Overview
  82. 6.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  84. 6.14.5 AmoyDx Recent Developments
  85. 6.15 Annoroad
  86. 6.15.1 Annoroad Company Information
  87. 6.15.2 Annoroad Business Overview
  88. 6.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  90. 6.15.5 Annoroad Recent Developments
  91. 6.16 Burning Rock Biotech
  92. 6.16.1 Burning Rock Biotech Company Information
  93. 6.16.2 Burning Rock Biotech Business Overview
  94. 6.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
  96. 6.16.5 Burning Rock Biotech Recent Developments
7 North America
  1. 7.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
  2. 7.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type
  3. 7.2.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
  4. 7.2.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2027-2032)
  5. 7.2.3 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type (2021-2032)
  6. 7.3 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
  7. 7.3.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
  8. 7.3.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2027-2032)
  9. 7.3.3 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2021-2032)
  10. 7.4 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country
  11. 7.4.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
  13. 7.4.3 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032)
  14. 7.4.4 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
  2. 8.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type
  3. 8.2.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
  4. 8.2.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2027-2032)
  5. 8.2.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type (2021-2032)
  6. 8.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
  7. 8.3.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
  8. 8.3.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2027-2032)
  9. 8.3.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2021-2032)
  10. 8.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country
  11. 8.4.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
  13. 8.4.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032)
  14. 8.4.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
  2. 9.2 China Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type
  3. 9.2.1 China Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
  4. 9.2.2 China Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2027-2032)
  5. 9.2.3 China Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type (2021-2032)
  6. 9.3 China Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
  7. 9.3.1 China Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
  8. 9.3.2 China Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2027-2032)
  9. 9.3.3 China Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
  2. 10.2 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type
  3. 10.2.1 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
  4. 10.2.2 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2027-2032)
  5. 10.2.3 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type (2021-2032)
  6. 10.3 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
  7. 10.3.1 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
  8. 10.3.2 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2027-2032)
  9. 10.3.3 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2021-2032)
  10. 10.4 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country
  11. 10.4.1 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
  13. 10.4.3 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032)
  14. 10.4.4 Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst